FindTrial
Sign In

The role of 18F-FDG-PET/CT in predicting the histopathological response following CRT in locally advanced rectal cancer

The role of 18F-FDG-PET/CT in predicting the histopathological response following CRT in locally advanced rectal cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000033141
Enrollment
Unknown
Registered
2020-05-22
Start date
2019-08-01
Completion date
Unknown
Last updated
2020-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rectal cancer

Interventions

Case series:radiotherapy/chemotherapy

Sponsors

The First Affiliated Hospital of Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 75 years old; 2. Patients with pathological diagnosis of locally advanced rectal cancer(LARC),( T3-,N0-2,M0) 3. Subjects signed an informed consent form prior to enrollment, indicating that they agreed to participate in the study

Exclusion criteria

Exclusion criteria: 1. Contraindications for MRI and PET; 2. Delayed surgery (8 months after CRT); 3. Other treatments other than CRT(eg.immunotherapy)before surgery; 4. distant metastasis; 5. Participated in other clinical trials within 3 months prior to inclusion; 6. Have a history of drug or contrast agents allergies; 7. Patients who have been determined by the investigator to have poor compliance with the study; 8.pregnancy or suspected pregnancy.

Design outcomes

Primary

MeasureTime frame
18F-FDG-PET / CT parameters;MRI parameters;TRG;—

Countries

China

Contacts

Public ContactXinlu Wang

The first affiliated hospital of guangzhou medical university

71lu@163.com+86 13226616001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026